Of course, India is not the only country in the world which has examined its pharmaceutical supply chains and concluded that it needs to balance its reliance on APIs and KSMs sourced from other regions with its own manufacturing capabilities.
In the US, pharma start-up Phlow Corporation was established to address what it terms as the US supply chain’s heavy dependence upon foreign suppliers, and bagged a contract worth up to $812 million to manufacture generics and APIs in shortage, funded by the US Biomedical Advanced Research and Development Authority (BARDA).
Phlow is leveraging use of continuous manufacturing processes as a viable alternative to traditional batch manufacturing – which it describes as a multi-step, lengthy process -- to produce APIs and finished pharmaceutical products, including those for COVID-19 pandemic response.
And in February 2020, French pharma company Sanofi announced its plans to create a European company to manufacture and market APIs – since named EUROAPI -- to help to balance the region’s heavy reliance on sourcing them from Asian markets.
At the political level, the European Commission is looking at establishing a future pharmaceutical and healthcare strategy roadmap, which will likely place the onus on making better use of